KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $91.3 million.

  • BioNTech SE's Income from Continuing Operations fell 3031.23% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$417.3 million, marking a year-over-year increase of 2857.8%. This contributed to the annual value of -$737.4 million for FY2024, which is 17367.4% down from last year.
  • Per BioNTech SE's latest filing, its Income from Continuing Operations stood at $91.3 million for Q3 2025, which was down 3031.23% from -$437.6 million recorded in Q2 2025.
  • BioNTech SE's Income from Continuing Operations' 5-year high stood at $7.1 billion during Q1 2022, with a 5-year trough of -$865.6 million in Q2 2024.
  • For the 5-year period, BioNTech SE's Income from Continuing Operations averaged around $1.6 billion, with its median value being $492.7 million (2023).
  • As far as peak fluctuations go, BioNTech SE's Income from Continuing Operations soared by 685753195802.68% in 2021, and later plummeted by 31749.74% in 2024.
  • BioNTech SE's Income from Continuing Operations (Quarter) stood at $3.6 billion in 2021, then tumbled by 35.81% to $2.3 billion in 2022, then crashed by 78.81% to $492.7 million in 2023, then dropped by 25.63% to $366.4 million in 2024, then crashed by 75.08% to $91.3 million in 2025.
  • Its Income from Continuing Operations was $91.3 million in Q3 2025, compared to -$437.6 million in Q2 2025 and -$437.4 million in Q1 2025.